Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis
16 juil. 2020 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, July 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
29 juin 2020 07h15 HE
|
Kiniksa Pharmaceuticals, Ltd.
Primary and all major secondary efficacy endpoints were highly statistically significant Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis events (primary efficacy...
Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19
17 juin 2020 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, June 17, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
10 juin 2020 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
- Rilonacept pivotal Phase 3 data in recurrent pericarditis expected in Q3 2020 - - Mavrilimumab Phase 2 data in GCA and KPL-404 Phase 1 data expected in Q4 2020 - - Management to provide a...
Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial
08 juin 2020 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, June 08, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus
11 mai 2020 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– Mavrilimumab treatment protocol in patients with severe COVID-19 pneumonia and hyperinflammation showed improved clinical outcomes compared to matched contemporaneous controls, including earlier...
Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity
28 avr. 2020 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– Financial guidance and clinical timelines for rilonacept, mavrilimumab, vixarelimab and KPL-404 remain intact amid COVID-19 pandemic –– Mavrilimumab treatment protocol in COVID-19 pneumonia and...
Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint
22 avr. 2020 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
- Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) at Week 8 -- Statistically significant secondary efficacy endpoint of...
Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session
30 mars 2020 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
- Phase 2 study data show the potential for rilonacept treatment to eliminate or reduce the risk of corticosteroid-associated morbidity in recurrent pericarditis - - Enrollment complete for the...
Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference
20 nov. 2019 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2nd Annual Evercore ISI HealthCONx Conference on...